Summary

Risk of thromboembolic events after recovery from SARS-CoV-2 infection

Enrique González-Revuelta1,2, Héctor Lago-Gancedo1,2, Borja Camacho-Montes1, Sonia Paola Leiva-Bisbicuth1,2, Marta Iglesias-Vela3, Jesús Seco-Calvo4

Affiliation of the authors

1Medicina de Familia y Comunitaria. G.A.P. León, Spain. 2Grupo de trabajo SEMESMIR-Castilla y León, Spain. 3Servicio de Urgencias. Complejo Asistencial Universitario de León, Spain. 4Instituto de Biomedicina (IBIOMED). Universidad de León, Spain.

DOI

Quote

González-Revuelta E, Lago-Gancedo H, Camacho-Montes B, Leiva-Bisbicuth SP, Iglesias-Vela M, Seco-Calvo J. Risk of thromboembolic events after recovery from SARS-CoV-2 infection. Rev Esp Urg Emerg. 2023;2:19–23

Summary

BACKGROUND. SARS-CoV-2 infection is associated with a high incidence of thromboembolic complications. However, whether or not a prothrombotic state persists after recovery is unknown.
MATERIAL AND METHODS. We undertook a case-control comparison of records from November 1, 2020, to March 31, 2021. Case records for patients treated for thromboembolic episodes in hospital emergency departments were selected; control patients were treated for other conditions in the same period. We recorded whether or not case and control patients had a history of recovery from COVID-19. Bivariate logistic regression was used to explore risk.
RESULTS. Records for 179 cases and 390 controls were selected. A majority of case patients had cerebrovascular stroke (30.2%) or acute coronary syndrome (21.2%). Only 17 cases (9.5%) and 390 controls (8.9%) had recently recovered from COVID-19. These datasuggest an odds ratio of 1.064 (95% CI, 0.58-1.96) for COVID-19 exposure as a predictor of thromboembolic episodes, although the model was underpowered (R2 = 0.028). The effect size was small for all variables, although the effect size for severity of SARS-CoV-2 infection was higher (0.2).
CONCLUSIONS. Our findings show that patients who have recovered from COVID-19 do not have a significantly higher risk of thromboembolic events than patients who have not recently recovered from this infection. Patients with a recent history of COVID-19 do not need to receive preventive anticoagulant treatment for longer periods than other patients.

 

More articles by the authors

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.